Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242725 | 0.82 | CALM1 (0.45) | CALM1CYP19A1IDO1TSHRALDH1A1 | |
| SCHEMBL1550020 | 0.82 | CALM1 (0.45) | CALM1CYP19A1IDO1TSHRALDH1A1 | |
| SCHEMBL15301728 | 0.79 | SMN1; SMN2 (0.37) | CALM1CYP19A1IDO1TSHRALDH1A1 | |
| SCHEMBL15302704 | 0.79 | SMN1; SMN2 (0.37) | CALM1CYP19A1IDO1TSHRALDH1A1 | |
| SCHEMBL2098666 | 0.78 | TP53 (0.43) | CALM1CYP19A1IDO1TSHRALDH1A1 | |
| SCHEMBL122439 | 0.78 | TP53 (0.43) | CALM1CYP19A1IDO1TSHRALDH1A1 | |
| SCHEMBL22689574 | 0.76 | CALM1 (0.39) | CALM1CYP19A1IDO1TSHRALDH1A1 | |
| SCHEMBL10318779 | 0.76 | CYP19A1 (0.43) | CALM1CYP19A1IDO1TSHRALDH1A1 | |
| SCHEMBL11240991 | 0.75 | CALM1 (0.50) | CALM1CYP19A1IDO1TSHRALDH1A1 | |
| SCHEMBL1728429 | 0.75 | CALM1 (0.50) | CALM1CYP19A1IDO1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025537-A | Atomic oxygen-resistant polyether-ether-ketone material for aviation, preparation method thereof and composite material | 南京工业大学 | 2025-05-23 | — | — | CN | claimed |
| CN-114249786-A | Preparation and application of nucleoside intermediate containing N, N-diacyl structure | 上海彩迩文生化科技有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-102911114-A | Synthetic method for 3, 5-dibromo-4-iodopyridine catalyzed by alkyl silicon reagent | UNIV XIHUA | 2013-02-06 | — | — | CN | claimed |
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | USV LIMITED (IN) | 2008-11-06 | — | — | US | claimed |
| WO-2007072507-A2 | POLYMORPHIC FORMS OF DOLASETRON BASE AND PROCESSES OF PREPARING DOLASETRON BASE, ITS POLYMORPHIC FORMS AND SALT THEREOF | USV LIMITED (IN) | 2007-06-28 | — | — | WO | claimed |
| US-6365643-B1 | Photoinitiators for cationic curing | TH. GOLDSCHMIDT AG (DE) | 2002-04-02 | — | — | US | claimed |
| US-5919552-A | Coated substrates and methods | XEROX CORPORATION (US) | 1999-07-06 | — | — | US | claimed |
| EP-0067066-B2 | Dry-developing resist composition | FUJITSU LTD (JP) | 1994-01-12 | — | — | EP | claimed |
| US-4614616-A | Process for preparing 3β7β-dihydroxy-Δ5 -steroids | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-09-30 | — | — | US | claimed |
| EP-0067066-B1 | DRY-DEVELOPING RESIST COMPOSITION | FUJITSU LIMITED (JP) | 1985-12-18 | — | — | EP | claimed |
| EP-0067067-B1 | DRY-DEVELOPING NEGATIVE RESIST COMPOSITION | FUJITSU LIMITED (JP) | 1985-09-25 | — | — | EP | claimed |
| US-4481366-A | Process for the preparation of a trifluorovinylsilane, and fluorine-containing polymer and process for its preparation | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1984-11-06 | — | — | US | claimed |
| US-4481279-A | Dry-developing resist composition | FUJITSU LIMITED (JP) | 1984-11-06 | — | — | US | claimed |
| EP-0119404-A1 | Fluorine-containing polymer and process for its preparation | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1984-09-26 | — | — | EP | claimed |
| US-4464455-A | Dry-developing negative resist composition | FUJITSU LIMITED (JP) | 1984-08-07 | — | — | US | claimed |
| EP-0051143-B1 | PROCESS FOR THE PREPARATION OF 3-BETA, 7-BETA-DIHYDROXY-DELTA-5 STEROIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-07-04 | — | — | EP | claimed |
| US-4416985-A | Process for preparing 3β,7β-dihydroxy-Δ5 -steroids | SCHERING, AKTIENGESELLSCHAFT (DE) | 1983-11-22 | — | — | US | claimed |
| EP-0067067-A2 | Dry-developing negative resist composition | FUJITSU LIMITED (JP) | 1982-12-15 | — | — | EP | claimed |
| EP-0067066-A2 | Dry-developing resist composition | FUJITSU LIMITED (JP) | 1982-12-15 | — | — | EP | claimed |
| EP-0051143-A1 | Process for the preparation of 3-beta, 7-beta-dihydroxy-delta-5 steroids | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-05-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275241-A1 | Polymorphic Forms of Dolasetron Base and Processes of Preparing Dolasetron Base, Its Polymorphic Forms and Salt Thereof | CYP4A11, CYP3A43, VKORC1 | CALM1 2960/4885CYP19A1 1406/4885IDO1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.